Skip to main content
Log in

Hepatorenal syndrome

Long-term treatment with terlipressin as a bridge to liver transplantation

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Summary

In patients with hepatorenal syndrome (HRS), 4-hr administration of a vasopressin analog has recently been shown to benefit renal blood flow and renal function. However, long-term effects and tolerance of this treatment have not been reported. We report a case of HRS that was controlled by the vasopressin analog, terlipressin. Because HRS repeatedly relapsed when treatment was discontinued, terlipressin, 2 mg/day was administered for 67 days, until liver transplantation could be performed in a patient with normal renal function. Except for limited cutaneous necrosis at an injection point, prolonged treatment with this vasopressin analog was well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Epstein M: Treatment of refractory ascites. N Engl J Med 321:1675–1677, 1989

    Google Scholar 

  2. Schrier R, Arroyo V, Bernardi M, et al: Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151–1157, 1988

    Google Scholar 

  3. Fernandez-Seara J, Prieto J, Quiroga J, et al: Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304–1312, 1989

    Google Scholar 

  4. Gerbes AL, Wernze H, Pilz A, et al: Effects of spironalactone and head-out water immersion on cirrhotic patients with and without ascites: Evidence for the vasodilatation hypothesis. Gastroenterology 98:A588, 1990

    Google Scholar 

  5. Lenz K, Druml W, Kleinberger G, et al: Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut 26:1385–1386, 1985

    Google Scholar 

  6. Lenz K, Hortnagl H, Druml W, et al: Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 30:90–96, 1989

    Google Scholar 

  7. Lenz K, Hornagl H, Druml W, et al: Ornipressin in the treatment of functional renal failure in decompensated cirrhosis. Gastroenterology 101:1060–1067, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganne-Carrié, N., Hadengue, A., Mathurin, P. et al. Hepatorenal syndrome. Digest Dis Sci 41, 1054–1056 (1996). https://doi.org/10.1007/BF02088218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02088218

Key words

Navigation